MWNA
COGT icon

Marshall Wace North America’s Cogent Biosciences COGT Stock Holding History

Marshall Wace North America’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$2.75M Buy
+327,332
New +$2.51M 0.01% 657

Other funds holding COGT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Marshall Wace North America's COGT Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Cogent Biosciences (COGT) in Q3 2021: 327,332 shares worth $2.75M. The stake represents 0.01% of the portfolio and ranks #657 among its holdings.

73 funds tracked by Wall St. Rank hold COGT as of Q3 2021.

  • Marshall Wace North America held 327,332 shares of Cogent Biosciences worth $2.75M as of Q3 2021.
  • Cogent Biosciences was a new Marshall Wace North America position in Q3 2021.
  • Cogent Biosciences made up 0.01% of Marshall Wace North America's portfolio in Q3 2021, its #657 holding.
  • 73 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.